#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Transfusion and Haematology Today / 2020 - 4

Treatment of Erdheim-Chester disease

Czech version

Authors: Z. Král 1;  M. Krejčí 1;  M. Ježová 2;  S. Ševčíková 3;  Z. Řehák 4;  R. Koukalová 4;  L. Pour 1;  Z. Adam 1
Authors‘ workplace: Interní hematologická a onkologická klinika LF MU a FN Brno 1;  Ústav patologie LF MU a FN Brno 2;  Ústav patologické fyziologie, LF MU, Brno 3;  Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno 4
Published in: Transfuze Hematol. dnes,26, 2020, No. 4, p. 271-277.
Category: Review/Educational Papers

Overview

Erdheim-Chester disease (ECD) is a rare form of histiocytosis, in present time ECD is classified as Langerhans-cell histiocytosis. It encompasses a spectrum of disorders ranging from asymptomatic bone lesions to multisystemic, life-threatening variants with CNS involvement. ECD prognosis is very variable. In this article, ECD treatment possibilities are widely discussed. The first line treatment is usually cladribine and the second line treatment is anakinra. ECD therapy is only partially effective with 50% treatment responses in various modalities at the maximum. ECD pathogenesis understanding has been widely improved with the discovery of MAPK pathway mutations, that have led to the use of targeted therapy (MEK and BRAF inhibitors) trials, with major efficacy. In the year 2020 BRAF and MEK inhibitors are recomended as first line treatment for severe CNS impairment, in other ECD cases the BRAF and MEK inhibitors are used as the second-line therapy.

Keywords:

Erdheim-Chester disease – cladribine – anakinra – vemurafenib – dabrafenib

Sources
  1. Haroche J, Cohen-Aubart F, Rollins BJ. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017;18:e113–e125.
  2. Papo M, Emile JF, Maciel TT, et al. Erdheim-Chester disease: a concise review. Curr Rheumatol Rep. 2019;21:66–72.
  3. Jendro MC, Zeidler H, Rosenthal H, et al. Improvement of Erdheim--Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol. 2004;23:52–56.
  4. Broccoli A, Stefoni V, Faccioli L, et al. Bilateral orbital Erdheim--Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. Rheumatol Int. 2012;32:2209–2213.
  5. Jeon IS, Lee SS, Lee MK. Chemotherapy and interferon-alpha treatment of Erdheim-Chester disease. Pediatr Blood Cancer. 2010;55:745–747.
  6. Bourke SC, Nicholson AG, Gibson GJ. Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax. 2003;58:1004–1005.
  7. Yano S, Kobayashi K, Kato K, et al. A case of Erdheim-Chester disease effectively treated by cyclophosphamide and prednisolone. Nihon Kokyuki Gakkai Zasshi. 2007;45:43–48.
  8. Gaspar N, Boudou P, Haroche J, et al. High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for adult histiocytic disorders with central nervous system involvement. Haematologica. 2006;91:1121–1125.
  9. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med. 2001;135:844–845.
  10. Cao XX, Niu N, Sun J, et al. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim--Chester disease. Ann Hematol. 2018;97:185–187.
  11. Wang JN, Qiu Y, Niu N, et al. Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy. Acta Oncol. 2020;59:302–305.
  12. Mascalchi M, Nencini P, Nistri M, et al. Failure of radiation therapy for brain involvement in Erdheim Chester disease. J Neurooncol. 2002;59:169–172.
  13. Katsunori M, Yasushi N, Masahiro H. Radiotherapy for Erdheim–-Chester disease. Int J Clin Oncol. 2007;12:238–241.
  14. Chicas Sett R, Pons Llanas O, Celada Álvarez F. A case report of recurrent adult-onset xanthogranuloma: is the radiotherapy a treat-ment option? Int Cancer Conf J. 2015;5:77–81.
  15. Blomstrand L, Thor A, Hagberg H. Erdheim-Chester disease presenting as periodontal disease: Experience of treatment with cladribine, interferon-a, local radiotherapy and anakinra. Acta Oncol. 2016;55:248–250.
  16. Matsui K, Nagata Y, Hiraoka M. Radiotherapy for Erdheim-Chester disease. Int J Clin Oncol. 2007;12:238–241.
  17. Miller R, Villá S, Kamer S, et al. Palliative treatment of Erdheim–-Chester disease with radiotherapy: a rare cancer network study. Radiother Oncol. 2006;80:323–326.
  18. Sivak-Callcot J, Rootman J, Rasmussen S, et al. Adult xanthogranulomatous disease of the orbit and ocular adnexa: new inmunohistochemical findings and clinical review. Br J Ophthalmol. 2006;90:602–608.
  19. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim–-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine. 2001;75:157–169.
  20. Singh V, Prajeeth CK, Gudi V, et al. 2-chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol. 2013;173: 288–297.
  21. Goyal G, Ravindran A, Young JR, et al. Mayo Clinic Histiocytosis Working Group. Clinicopathological features,treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020;105:348–357.
  22. Adam Z, Řehák Z, Koukalová R, et al. PET-CT dokumentovaná kompletní 4letá remise Erdheimovy-Chesterovy nemoci po léčbě kladribinem. Vnitřní Lék. 2014;60:499–511.
  23. Azadeh N, Tazelaar HD, Gotway MB, et al. Erdheim Chester Disease treated successfully with cladribine. Respir Med Case Rep. 2016;8:37–40.
  24. Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88:844–847.
  25.  Perić P, Antić B, Knezević-Usaj S, et al. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis. Vojnosanit Pregl. 2016;73:83–87.
  26. Rajendra B, Duncan A, Parslew R, et al. Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer. 2009;52:413–415.
  27. Sheidow TG, Nicolle DA, Heathcote JG. Erdheim-Chester disease: two cases of¨orbital involvement. Eye (Lond). 2000;14:606–612.
  28. Sutton L, Sutton S, Sutton M. Treatment of necrobiotic xanthogranuloma with 2-chlorodeoxyadenosine. Skinmed. 2013;11:121–123.
  29. Tamura S, Kawamoto K, Miyoshi H, et al. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. J Clin Exp Hematol. 2018;58:161–165.
  30. Goyal G, Shah MV, Call TG, et al. Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease. JAMA Oncol. 2017;3:1253–1256.
  31. Esmaeli B, Ahmadi A, Tang R, et al. Interferon therapy for orbital infiltration secondary to Erdheim-Chester disease. Am J Ophthalmol. 2001;132:945–947.
  32. Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106:2992–2994.
  33. Suzuki HI, Hosoya N, Miyagawa K, et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res. 2010;34:e21–e24.
  34. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54:3330–3336.
  35. Hervier B, Arnaud L, Charlotte F, et al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-α. Semin Arthritis Rheum. 2012;41:1–7.
  36. Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon are independent prognostic factors in Erdheim--Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778–2782.
  37. Diamond Elm, Dagna L, Hyman D, et al. Consensus guidelines for the diagnosis and clinical mamagement of Erdheim Chester disease. Blood. 2014;124:483–492.
  38. Bulycheva EN, Baykov VV, Zaraĭskiĭ MI, et al. Rare form of Erdheim--Chester disease presenting with isolated central skeletal lesions treated with a combination of alfa-interferon and zoledronic acid. Case Rep Hematol. 2015;20:5–7.
  39. Suzuki HI, Hosoya N, Miyagawa K, et al. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha. Leuk Res. 2010;34:e21–e24.
  40. Tezol O, Citak EC, Ayhan YS, et al. Effective high-dose interferon-αtherapy in a 13-year-old girl with Erdheim-Chester disease. J Pediatr Hematol Oncol; publikováno elektronicky 27. června 2019. DOI 10.1097/MPH.0000000000001538.]
  41. Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116:4070–4076.
  42. Podestà MA, Graziani G, Reggiani F, et al. Improvement of Erdheim--Chester disease-related renal failure after treatment with anakinra. Kidney Res Clin Pract. 2014;33:165–167.
  43. Szturz P, Adam Z, Rehák Z, et al. Xanthelasma palpebrarum re-sponding to interleukin-1 blockade. Intern Med. J 2014;44:617–618.
  44. Darstein F, Kirschey S, Heckl S, et al. Successful treatment of Erdheim-Chester disease with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. Intern Med. J 2014;44:90–92.
  45. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erd-heim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine. 2014;81:175–177.
  46. Killu AM, Liang JJ, Jaffe AS. Erdheim-Chester disease with cardiac involvement successfully treated with anakinra. Int J Cardiol. 2013;167:e115–117.
  47. Aubert O, Aouba A, Deshayes S, et al. Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine. 2013;80:206–207.
  48. Tran TA, Pariente D, Lecron JC, et al. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum. 2011;63:4031–4032.
  49. Cohen-Aubart F, Maksud P, Saadoun D, et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood. 2016;127:1509–1512.
  50. Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol. 2018;183:520–524.
  51. Franconieri F, Deshayes S, de Boysson H, et al. Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. Oncoimmunol. 2018;7:e1450712.
  52. Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30:e286–e290.
  53. Ferrero E, Belloni D, Corti A et al. TNF-alpha in ECD pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology. 2014;53:198–200.
  54. Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol. 2018;183:520–524.
  55. Cohen-Aubart F, Maksud P, Emile J-F, et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis. 2018;77:1387–1390.
  56. Jia X, Ning X, Bai Q, et al. Combination of adalimumab with lower dose of methylprednisolone in Erdheim-Chester disease with systemic involvement. Acta Oncol. 2017;56:753–756.
  57. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008;111:5413–5415.
  58. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Engl J Med. 2004;351:1034–1035.
  59. Utikal J, Ugurel S, Kurzen H, et al. Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. Arch Dermatol. 2007;143:736–740.
  60. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations inErdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;27;120:2700–2703.
  61. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:149–500.
  62. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:26–736.
  63. Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6:154–165
  64. Emile J-F, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124:3016–3019.
  65. Cohen-Aubart F, Emile JF, Maksud P, et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology. 2014;83:1294–1296.
  66. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521–524.
  67. Euskirchen P, Haroche J, Emile JF, et al. Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflamm. 2015;2:e78.
  68. Franconieri F, Martin-Silva N, de Boyssson H, et al. A. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncol. 2016;55:930–930.
  69. Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E) mutated Erdheim-Chester disease. J Clin Oncol. 2015;33:411–418.
  70. Schirmer JH, Thorns C, Moosig F, et al. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib. Rheumatology (Oxford). 2015;54:1932–1934.
  71. Tzoulis C, Schwarzlmüller T, Gjerde IO, et al. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report. BMC Res Notes. 2015;8:171.
  72. Oneal PA, Kwitkowski V, Luo L, e al. FDA Approval Summary: Vemurafenib for the treatment of patients with Erdheim-Chester Disease with the BRAFV600 mutation. Oncologist. 2018;23:1520–1524.
  73. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4:384–388.
  74. Cohen Aubart F, Emile J-F, Carrat F, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood. 2017;130:1377–1380.
  75. Bhatia A, Hatzoglou V, Ulaner G, et al. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. Neuro Oncol 2020; publikováno elektronicky 17. ledna 2020. DOI 10.1093/neuonc/noaa008.
  76. Grob JJ., Amonkar MM., Karaszewska B. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol. 2015;16:1389–1398.
  77. Al Bayati A, Plate T, Al Bayati M, et al. Dabrafenib and trametinib treatment for Erdheim-Chester Disease with brain stem involvement. Mayo Clin Proc Innov Qual Outcomes. 2018;2:303–308.
  78. Sanders IM, Goodman A, Kurzrock R. Real word toxicity experience with BRAF/MEK inhibitors in pacients with Erdheim-Chester disease. The Oncologist 2019;24:1–5.
  79. Fernández-Eulate G, Muñoz-Lopetegi A, Ruiz I, et al. Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement. BMJ Case Rep. 2019;12:25–27.
  80. Van Keerberghen CA, Harrouk A, Leone L. A new role for fluorine-18-fluorodeoxyglucose positron-emission tomography/computed tomography in Erdheim-Chester disease. World J Nucl Med. 2019;18:201–203.
  81. Kinkor Z. Závažné plicní postižení u Erdheim-Chesterovy nemoci (kazuistika). Česko-slov Patol Soudní Lék. 2001;37:114–117.
  82. Řehák Z, Koukalová R, Vašina J, et al. 18F-FDG PET/CT obraz Erdheimovy-Chesterovy nemoci – přehled českých pacientů. Nukleární Medicína. 2018;7:50–56.
Labels
Haematology Internal medicine Clinical oncology
Tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients in both clinical trials and daily clinical practice
Targeted degradation of undruggable, malignant haematological disorder-causing proteins using bifunctional molecules, exploiting polyubiquitination and degradation in proteasomes
Actual role of allogeneic haematopoietic transplantation in the treatment of acute myeloid leukaemia
Necrobiotic xanthogranuloma associated with monoclonal gammopathy: case report and overview of therapeutic options
Still´s disease – a rare autoinflammatory illness of adults: case report and overview of therapeutic options
Hereditary thrombocytopenia caused by a pathogenic variant of the MYH9 gene diagnosed in an adult woman
Recommendations for screening, diagnosis, prophylaxis and treatment of hepatitis in haemato-oncological patients – CELL recommendations
Dopisy redakci
Dopisy redakci
Za pani profesorkou MUDr. Adrienou Sakalovou, DrSc.
Zemřela MUDr. Zdeňka Vorlová, CSc.
Jubileum prof. MUDr. Vlastimila Ščudly, CSc.
Article was published in

Transfusion and Haematology Today

Issue 4
2020 Issue 4
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#